Related Experiment Video
Updated: May 28, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
COVID-19 Infections Still Occur: How Do Pregnant and Non-Pregnant Individuals Compare? A Study from the Canadian
Anick Bérard1,2,3, Odile Sheehy1, Padma Kaul4
1Research Center, CHU Ste-Justine, Montreal, QC H3T 1C5, Canada.
Insights
Pregnant individuals with COVID-19 face increased risks of adverse outcomes like spontaneous abortion and prematurity. Early treatment with medications can mitigate these risks, emphasizing the need for continued surveillance during pregnancy.
Area of Science:
- Obstetrics and Gynecology
- Infectious Diseases
- Public Health
Background:
- Over 100 million pregnant individuals globally are at risk of COVID-19.
- Understanding COVID-19's impact on pregnancy and neonatal outcomes is crucial.
Purpose of the Study:
- To compare severe COVID-19 prevalence in pregnant versus non-pregnant individuals of reproductive age.
- To assess the risk of adverse pregnancy and neonatal outcomes associated with COVID-19 during gestation.
Main Methods:
- Utilized data from the Canadian Mother-Child Cohort (February 2020-2021).
- Included pregnant individuals with completed trimesters and non-pregnant individuals (aged 15-45) with positive COVID-19 tests.
- Quantified associations using log-binomial regressions, categorizing severity by hospitalization.
Main Results:
- COVID-19 in pregnancy was linked to higher risks of spontaneous abortion, gestational diabetes, prematurity, and NICU admission.
- Maternal age was significantly lower in pregnant individuals diagnosed with COVID-19.
- Medication treatment for COVID-19 reduced the risks of adverse outcomes.
Conclusions:
- Severe COVID-19 is more prevalent in pregnancy and associated with increased maternal and neonatal risks.
- Continued surveillance during pregnancy is vital for preventing adverse outcomes, especially as preventive strategies are relaxed.
- Early medical intervention for COVID-19 in pregnant individuals can mitigate negative consequences.
Abstract:
Over 100 million pregnant people worldwide remain at risk of COVID-19. We compared the prevalence of severe COVID-19 in pregnancy and in people of reproductive age, and the risk of adverse pregnancy/neonatal outcomes in those with/without COVID-19 during gestation. In the Canadian Mother-Child Cohort, two sub-cohorts were identified using medical services, prescription medication fillings, hospitalizations, and COVID-19 surveillance testing programs data (28 February 2020-2021). The first included all pregnant people with at least one completed trimester of pregnancy during the study period, stratified on COVID-19 status. The second included all non-pregnant people (aged 15-45) with a positive COVID-19 test during the same period. COVID-19 severity was categorized based on hospital admissions before the end of pregnancy. Associations between COVID-19 during pregnancy and adverse perinatal outcomes were quantified using log-binomial regressions. A total of 150,345 pregnant people (3464 (2.3%) had COVID-19), and 112,073 non-pregnant people with COVID-19 were included. Maternal age at the time of COVID-19 diagnosis/positive test was statistically significantly lower among pregnant individuals compared to those who were not pregnant (96% had less than 40 years vs. 80%, p < 0.001). In pregnancy, COVID-19 was associated with the risk of spontaneous abortions (adjRR 1.76, 95%CI 1.37, 2.25), gestational diabetes (adjRR 1.52, 95%CI 1.18, 1.97), prematurity (adjRR 1.30, 95%CI 1.01, 1.67), and NICU (adjRR 1.32, 95%CI 1.10, 1.59); COVID-19 treatment with medications reduced risks. Severe COVID-19 was more prevalent in pregnancy and was associated with higher risks of adverse maternal/neonatal outcomes. As some countries are pulling back preventive strategies for COVID-19, this study highlights the importance of continued surveillance during pregnancy to prevent adverse pregnancy outcomes.
More Related Videos
08:08Determination of the Transport Rate of Xenobiotics and Nanomaterials Across the Placenta using the ex vivo Human Placental Perfusion Model
Published on: June 18, 2013
05:13Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
Published on: February 28, 2025
Related Concept Videos
Teratogenicity
Mutagenicity and Carcinogenicity
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Development of the Oral Microbiota
Cytomegalovirus Disease